Boehringer Ingelheim
Boehringer’s spesolimab data raises hope for serious skin disease
Phil Taylor
Boehringer Ingelheim, dermatology, Immunology and inflammation, rare disease, spesolimab
0 Comment
Boehringer invests again in AI diagnosis specialist Brainomix
Phil Taylor
Boehringer Ingelheim, Brainomix, digital, digital health, fibrosis, financing, Oncology, stroke
0 Comment
Boehringer-backed digital health academy set for launch in UK
Phil Taylor
Boehringer Ingelheim, digital, digital health, NHS, ORCHA, Training
0 Comment
R&D/ Views & Analysis/ Views and analysis
Legal requirement, ethical duty: How to develop compliant, useful lay summaries
Amanda Barrell
Boehringer Ingelheim, clinical trials, EFPIA, GLP, medical writing
0 Comment
Patients/ Views & Analysis/ Views and analysis
Co-inspiration: Listen and learn to overcome patient-centricity barriers
Amanda Barrell
Boehringer Ingelheim, patient centricity, patients
0 Comment
News/ News/ Sales and Marketing
FDA clears first “interchangeable” Humira biosimilar
Phil Taylor
AbbVie, biosimilar, Boehringer Ingelheim, Cyltezo, Humira, immunology, regulatory approval
0 Comment
NICE changes stance on Sanofi’s Dupixent for severe asthma
Phil Taylor
Boehringer Ingelheim, HEOR, NHS, NICE, Ofev, rare disease, Regeneron, respiratory, Sanofi, severe asthma
0 Comment
Boehringer buys Abexxa, bolstering its immuno-oncology pipeline
Phil Taylor
abexxa, Boehringer Ingelheim, immuno-oncology, M&A, Oncology
0 Comment